We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current MDP market cap is 54.05M. The company's latest EPS is USD -0.0087 and P/E is -254.02.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 74.36M | 79.66M | 76.7M | 108.1M | 113.05M |
| Operating Income | -4.87M | -294k | -14.91M | 7.88M | 11.08M |
| Net Income | -6.24M | -28.26M | -2.88M | 1.22M | -214k |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 174.17M | 148.51M | 139.23M | 161.33M | 155.73M |
| Total Liabilities | 139.74M | 130.5M | 121.43M | 138.88M | 125.41M |
| Total Equity | 34.44M | 18.02M | 17.79M | 22.45M | 30.32M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -2.3M | 5.04M | -1.18M | -1.44M | 18.71M |
| Investing | -40.52M | -11.7M | -8.2M | -1.72M | -3.48M |
| Financing | 20.71M | 18.68M | 663k | 6.41M | -23.05M |
| Market Cap | 54.05M |
| Price to Earnings Ratio | -254.02 |
| Price to Sales Ratio | 0.48 |
| Price to Cash Ratio | 10.28 |
| Price to Book Ratio | 1.78 |
| Dividend Yield | - |
| Shares Outstanding | 24.46M |
| Average Volume (1 week) | 19.86k |
| Average Volume (1 Month) | 47.78k |
| 52 Week Change | 7.80% |
| 52 Week High | 3.53 |
| 52 Week Low | 1.44 |
| Spread (Intraday) | 0.04 (1.78%) |
| Company Name | Medexus Pharmaceuticals Inc |
| Address |
35 nixon road, unit 1 bolton L7E 1K1 |
| Website | https://www.medexus.com |
| Industry | blank checks (6770) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
